Rigel Pharmaceuticals Inc (RIGL) Stock Analysis

Rigel Pharmaceuticals Inc (RIGL) is a publicly traded company in the HEALTHCARE sector. It trades at $30.02, carries a market capitalization of $552.47M, a price-to-earnings ratio of 1.55. This page summarizes the public market data, fundamentals, and frequently asked questions for RIGL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Rigel Pharmaceuticals Inc currently has a Bullish sentiment score of 0.16.

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. is a biotechnology company based in South San Francisco, California, specializing in the discovery and development of novel small molecule drugs aimed at addressing critical unmet medical needs in blood disorders, cancer, and rare immune diseases. With a strong focus on innovative therapies, Rigel leverages its proprietary drug development platform to advance its pipeline of targeted treatments, aiming to improve patient outcomes in challenging therapeutic areas. T...

GNG Research Analysis

GNG Research scores Rigel Pharmaceuticals Inc (RIGL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RIGL.

Frequently Asked Questions

Does RIGL pay dividends?

Rigel Pharmaceuticals Inc (RIGL) does not currently pay a regular dividend.

What is RIGL's P/E ratio?

Rigel Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 1.55.

What is RIGL's market cap?

Rigel Pharmaceuticals Inc (RIGL) has a market capitalization of $552.47M with a current stock price of $30.02.